Evaluation of the FARAFLEX Mapping and Pulsed Field Ablation System in Subjects With Atrial Fibrillation
A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 571 participants.
Also called NCT07575269
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 571 participants
- Sponsor
- Registry
-
NCT07575269
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Belgium, Ireland, Spain
- Registry status
- Recruiting
Technical summary
Registry record NCT07575269. Allocation not applicable; no masking; primary purpose treatment. Start 2026-07-07 (actual); primary completion 2028-07-20 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluation of the FARAFLEX Mapping and Pulsed Field Ablation System in Subjects With Atrial Fibrillation
- Acronym
- FARADIGM
- Condition
- Paroxysmal Atrial Fibrillation (PAF)
- Condition
- Persistent Atrial Fibrillation
- Intervention (Device)
- FARAFLEX Mapping and Pulsed Field Ablation (PFA) System
- Lead sponsor
- Boston Scientific Corporation
Record details
- Record id
cardio:ct-nct07575269- Content hash
c5c62a15bad11e6dfea23f80be9fdadf6dc3b383bd24d7d6c428dc323a667db4